IO Biotech Inc(IOBT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.23 | Insider Own | 6.63% | Shs Outstand | 72.0M | Perf Week | - |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 59.09% | Insider Trans | - | Shs Float | 38.3M | Perf Month | -72.57% |
| Enterprise Value | - | PEG | - | EPS next Q | -0.14 | Inst Own | 46.74% | Short Float | 5.62% | Perf Quarter | -91.04% |
| Income | - | P/S | - | EPS this Y | 34.83% | Inst Trans | - | Short Ratio | 0.11 | Perf Half Y | -92.52% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 2.15M | Perf YTD | -92.12% |
| Book/sh | - | P/C | - | EPS past 3/5Y | 17.72% - | ROE | - | 52W High | -98.28% ($2.79) | Perf Year | -95.12% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 73.29% ($0.03) | Perf 3Y | -97.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.36% | Gross Margin | - | Volatility(W/M) | 47.81% 24.07% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 23.79 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -72.22% ($0.18) | Beta | 0.75 | Target Price | $2.18 |
| Payout | - | Debt/Eq | - | Earnings | 2026/03/04 | SMA50 | -82.21% ($0.28) | Rel Volume | 0 | Prev Close | $0.05 |
| Employees | 80 | LT Debt/Eq | - | EPS/Sales Surpr. | 59.88% - | SMA200 | -94.95% ($0.99) | Avg Volume(3M) | 20.39M | Price | $0.05 |
| IPO | 2021/11/5 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🔬 IO Biotech (IOBT) is a biotechnology company specializing in the research and development of innovative cancer treatment vaccines and novel immuno-oncology therapies designed to block immune inhibitory pathways, thereby enabling the immune system to mount a self-attack against cancer cells.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +34.8% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -97.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 46.7%.
Tap to view numbers
It ranks #556 of 596 in the industry
Based on market cap of $3M.
KALA#554 Kala Bio Inc $4M PER - 
ENLV#555 Enlivex Ltd $3M PER - IOBT#556 IO Biotech Inc $3M PER - 
CVKD#556 Cadrenal Therapeutics Inc $3M PER - 
ERNA#557 Ernexa Therapeutics Inc $3M PER - 
FAQ
What kind of company is IOBT?
IOBT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IOBT?
The market cap of IOBT is approximately $3M, ranking 5,729 within its sector.
What is the 52-week high and low for IOBT?
IOBT has recorded a 52-week high of $2.79 and a low of $0.03.
